Find Caspofungin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF DossiersDRUG PRODUCT COMPOSITIONS

39RELATED EXCIPIENT COMPANIES

79EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Cancidas, Caspofungin diacetate, 179463-17-3, Mk 0991, L 743872, Cancidas (tn)
Molecular Formula
C56H96N10O19
Molecular Weight
1213.4  g/mol
InChI Key
OGUJBRYAAJYXQP-LLXMLGLCSA-N

Caspofungin
A cyclic lipopeptide echinocandin and beta-(1,3)-D-glucan synthase inhibitor that is used to treat internal or systemic MYCOSES.
1 2D Structure

Caspofungin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
acetic acid;N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-21-(2-aminoethylamino)-3-[(1R)-3-amino-1-hydroxypropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide
2.1.2 InChI
InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+;;/m1../s1
2.1.3 InChI Key
OGUJBRYAAJYXQP-LLXMLGLCSA-N
2.1.4 Canonical SMILES
CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O
2.1.5 Isomeric SMILES
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Cancidas

2. Caspofungin

3. Caspofungin Msd

4. L 743,872

5. L 743872

6. L-743,872

7. L-743872

8. L743,872

9. L743872

10. Mk 0991

11. Mk-0991

12. Mk0991

2.2.2 Depositor-Supplied Synonyms

1. Cancidas

2. Caspofungin Diacetate

3. 179463-17-3

4. Mk 0991

5. L 743872

6. Cancidas (tn)

7. Mk-0991

8. Caspofungin Acetate- Bio-x

9. Schembl149293

10. L 743873

11. Chembl4297142

12. Caspofungin Acetate (jan/usan)

13. Mfcd08141839

14. Akos025401982

15. Ac-27763

16. Bc164293

17. D02501

18. F20901

19. 463c173

2.3 Create Date
2006-06-06
3 Chemical and Physical Properties
Molecular Weight 1213.4 g/mol
Molecular Formula C56H96N10O19
Hydrogen Bond Donor Count18
Hydrogen Bond Acceptor Count22
Rotatable Bond Count23
Exact Mass1212.68532087 g/mol
Monoisotopic Mass1212.68532087 g/mol
Topological Polar Surface Area487 Ų
Heavy Atom Count85
Formal Charge0
Complexity1930
Isotope Atom Count0
Defined Atom Stereocenter Count14
Undefined Atom Stereocenter Count2
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameCaspofungin acetate
Active IngredientCaspofungin acetate
Dosage FormInjectable
Routeinjection
Strength70mg/vial; 50mg/vial
Market StatusTentative Approval
CompanySandoz

2 of 2  
Drug NameCaspofungin acetate
Active IngredientCaspofungin acetate
Dosage FormInjectable
Routeinjection
Strength70mg/vial; 50mg/vial
Market StatusTentative Approval
CompanySandoz

4.2 Drug Indication

- Treatment of invasive candidiasis in adult or paediatric patients.

- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.


Fungal infections


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antifungal Agents

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)


Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Lipopeptides [CS]; Echinocandin Antifungal [EPC]
5.3 ATC Code

J02AX04


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 27585

Submission : 2013-11-27

Status : Active

Type : II

CCSB Company Banner

02

Tapi Nl Bv

Israel
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2014-04-14

Pay. Date : 2013-03-20

DMF Number : 26978

Submission : 2013-06-21

Status : Active

Type : II

TAPI Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 22770

Submission : 2009-05-12

Status : Inactive

Type : II

TAPI Company Banner

04

PharmaVenue
Not Confirmed

05

Gland Pharma Ltd

India

USDMF

arrow
PharmaVenue
Not Confirmed

06

PharmaVenue
Not Confirmed

06

PharmaVenue
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-01-05

Pay. Date : 2014-08-12

DMF Number : 28472

Submission : 2014-11-20

Status : Active

Type : II

blank

07

Lek Pharmaceuticals Dd

Slovenia

USDMF

arrow
PharmaVenue
Not Confirmed

07

PharmaVenue
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 23222

Submission : 2009-10-28

Status : Inactive

Type : II

blank

08

PharmaVenue
Not Confirmed

08

PharmaVenue
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-09-22

Pay. Date : 2020-08-12

DMF Number : 33532

Submission : 2019-02-28

Status : Active

Type : II

blank

09

PharmaVenue
Not Confirmed

10

PharmaVenue
Not Confirmed
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - POWDER;INTRAVENOUS - 50MG/VIAL

USFDA APPLICATION NUMBER - 21227

read-more

DOSAGE - POWDER;INTRAVENOUS - 70MG/VIAL

USFDA APPLICATION NUMBER - 21227

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Taste Masking

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Parenteral

read-more
read-more

Co-Processed Excipients

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Granulation

read-more
read-more

Coating Systems & Additives

read-more
read-more

Solubilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 179463-17-3 / Caspofungin API manufacturers, exporters & distributors?

Caspofungin manufacturers, exporters & distributors 1

94

PharmaCompass offers a list of Caspofungin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Caspofungin manufacturer or Caspofungin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Caspofungin manufacturer or Caspofungin supplier.

PharmaCompass also assists you with knowing the Caspofungin API Price utilized in the formulation of products. Caspofungin API Price is not always fixed or binding as the Caspofungin Price is obtained through a variety of data sources. The Caspofungin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Caspofungin

Synonyms

Cancidas, Caspofungin diacetate, 179463-17-3, Mk 0991, L 743872, Cancidas (tn)

Cas Number

179463-17-3

About Caspofungin

A cyclic lipopeptide echinocandin and beta-(1,3)-D-glucan synthase inhibitor that is used to treat internal or systemic MYCOSES.

CASPO Manufacturers

A CASPO manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CASPO, including repackagers and relabelers. The FDA regulates CASPO manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CASPO API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of CASPO manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

CASPO Suppliers

A CASPO supplier is an individual or a company that provides CASPO active pharmaceutical ingredient (API) or CASPO finished formulations upon request. The CASPO suppliers may include CASPO API manufacturers, exporters, distributors and traders.

click here to find a list of CASPO suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

CASPO USDMF

A CASPO DMF (Drug Master File) is a document detailing the whole manufacturing process of CASPO active pharmaceutical ingredient (API) in detail. Different forms of CASPO DMFs exist exist since differing nations have different regulations, such as CASPO USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A CASPO DMF submitted to regulatory agencies in the US is known as a USDMF. CASPO USDMF includes data on CASPO's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CASPO USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of CASPO suppliers with USDMF on PharmaCompass.

CASPO JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The CASPO Drug Master File in Japan (CASPO JDMF) empowers CASPO API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the CASPO JDMF during the approval evaluation for pharmaceutical products. At the time of CASPO JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of CASPO suppliers with JDMF on PharmaCompass.

CASPO KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a CASPO Drug Master File in Korea (CASPO KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CASPO. The MFDS reviews the CASPO KDMF as part of the drug registration process and uses the information provided in the CASPO KDMF to evaluate the safety and efficacy of the drug.

After submitting a CASPO KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CASPO API can apply through the Korea Drug Master File (KDMF).

click here to find a list of CASPO suppliers with KDMF on PharmaCompass.

CASPO WC

A CASPO written confirmation (CASPO WC) is an official document issued by a regulatory agency to a CASPO manufacturer, verifying that the manufacturing facility of a CASPO active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CASPO APIs or CASPO finished pharmaceutical products to another nation, regulatory agencies frequently require a CASPO WC (written confirmation) as part of the regulatory process.

click here to find a list of CASPO suppliers with Written Confirmation (WC) on PharmaCompass.

CASPO NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CASPO as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for CASPO API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture CASPO as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain CASPO and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CASPO NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of CASPO suppliers with NDC on PharmaCompass.

CASPO GMP

CASPO Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of CASPO GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CASPO GMP manufacturer or CASPO GMP API supplier for your needs.

CASPO CoA

A CASPO CoA (Certificate of Analysis) is a formal document that attests to CASPO's compliance with CASPO specifications and serves as a tool for batch-level quality control.

CASPO CoA mostly includes findings from lab analyses of a specific batch. For each CASPO CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

CASPO may be tested according to a variety of international standards, such as European Pharmacopoeia (CASPO EP), CASPO JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CASPO USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty